Hypolipidemic effect of silymarin in dyslipidaemia of different etiologies
المؤلفون المشاركون
Husayn, Sad Abd al-Rahman
Mishimish, Bahir Abd al-Razzaq
Ismail, Sijidah Husayn
Husayn, Khalid Ibrahim
Sulayman, Amal Ajawid
المصدر
Journal of the Faculty of Medicine Baghdad
العدد
المجلد 49، العدد 4 (31 ديسمبر/كانون الأول 2007)، ص ص. 449-456، 8ص.
الناشر
تاريخ النشر
2007-12-31
دولة النشر
العراق
عدد الصفحات
8
التخصصات الرئيسية
الموضوعات
الملخص EN
Background : Many drug and non drug approaches are utilized for the treatment of dyslipidemia ; flavonoids, the major constituents of silymarin, have been proved to positively modify lipoproteins in experimentally-induced dyslipidemia.
Objective : This study was designed to evaluate the effect of silymarin, when used alone or in combination with other hypolipidemic agents, on the lipid profile in dyslipidemic patients.
Fac Med Baghdad Patients and Methods : Fifty seven patients with dyslipidaemia of various etiologies are involved in this clinical trial.
They are randomized into three groups treated with either 400 mg / day silymarin (gr.
A) or 20 mg / day lovastatin (gr.
B) or a combination of 200 mg / day silymarin and 10 mg / day lovastatin (gr.
C) for 2 months, only 45 patients complete the study.
Serum lipid profile (total cholesterol, triglycerides, LDLC, VLDL-C and HDL-C) and liver functions indices (SGOT, SGPT, total bilirubin) were evaluated each month during the follow up period.
Results : Treatment with silymarin results in a significant decrease in TC, TG, LDL-C and VLDL-C levels, with a significant elevation in HDL-C levels, without any significant changes in liver function.
Meanwhile, adjunct use of silymarin with lovastatin widens the scope of lovastatin-hypolipidemic effect, without increasing in the score of adverse effects, and ameliorating the hepatic damage emerged due to its use.
Conclusions : The results presented in this study indicated that silymarin can be used alone in clinical practice for the treatment of dyslipidemia, and when combined with other hypolipidemic agents like lovastatin, improves therapeutic profile and ameliorate some of its adverse effects.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Mishimish, Bahir Abd al-Razzaq& Husayn, Sad Abd al-Rahman& Ismail, Sijidah Husayn& Husayn, Khalid Ibrahim& Sulayman, Amal Ajawid. 2007. Hypolipidemic effect of silymarin in dyslipidaemia of different etiologies. Journal of the Faculty of Medicine Baghdad،Vol. 49, no. 4, pp.449-456.
https://search.emarefa.net/detail/BIM-339232
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Mishimish, Bahir Abd al-Razzaq…[et al.]. Hypolipidemic effect of silymarin in dyslipidaemia of different etiologies. Journal of the Faculty of Medicine Baghdad Vol. 49, no. 4 (2007), pp.449-456.
https://search.emarefa.net/detail/BIM-339232
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Mishimish, Bahir Abd al-Razzaq& Husayn, Sad Abd al-Rahman& Ismail, Sijidah Husayn& Husayn, Khalid Ibrahim& Sulayman, Amal Ajawid. Hypolipidemic effect of silymarin in dyslipidaemia of different etiologies. Journal of the Faculty of Medicine Baghdad. 2007. Vol. 49, no. 4, pp.449-456.
https://search.emarefa.net/detail/BIM-339232
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references : p. 455-456
رقم السجل
BIM-339232
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر